Pulmonary structural cells

Pulmonary structural cells represent the collective resident cell populations of the lung, including airway and alveolar epithelial cells, vascular endothelial cells, fibroblasts, and smooth muscle cells [1][2]. These cells are essential for maintaining the lung's architectural integrity, facilitating gas exchange, and providing a primary barrier against environmental insults [3]. Beyond their structural roles, they actively modulate immune responses and tissue repair through the secretion of cytokines, chemokines, and extracellular matrix components [4]. In chronic respiratory conditions like asthma, COPD, and idiopathic pulmonary fibrosis (IPF), these cells become central drivers of pathology through processes such as airway remodeling, myofibroblast differentiation, and impaired barrier function [5][6]. Consequently, they are the primary focus of various therapeutic interventions, ranging from bronchodilators that relax smooth muscle to anti-fibrotic agents that inhibit fibroblast activation [7]. Understanding the complex signaling networks within these cells is vital for the development of targeted therapies that can halt or reverse disease progression in the lungs [1]. While not a single molecular target, the functional state of these cells serves as a critical endpoint for evaluating drug efficacy in pulmonary medicine [5].

Other names

Lung structural cellsResident pulmonary cellsAirway structural cells

Therapeutic agents target specific molecular pathways within these cells, such as activating beta-2 adrenergic receptors on smooth muscle cells to induce bronchodilation or inhibiting tyrosine kinase signaling in fibroblasts to prevent fibrosis [6][7].